Group 1 - Shares in Agios Pharmaceuticals experienced a significant decline of 50% following mixed results from its Phase 3 trial of the sickle cell disease drug, mitapavit [1] - The Phase 3 trial had two primary endpoints, achieving success in one while failing to meet the other [2] - The trial demonstrated a statistically significant response in average hemoglobin levels, with 40.6% of treated patients showing improvement compared to 2.9% in the placebo group [3] Group 2 - Despite the failure to significantly reduce sickle cell pain crises (SCPCs), management highlighted the potential value of mitapavit due to its "anti-hemolytic profile" [5][7] - The company plans to engage with the FDA and submit a marketing application for mitapavit in the first quarter of 2026 [5][7] - The market reaction to the trial results suggests a potential overreaction, indicating that there may still be investment opportunities in Agios Pharmaceuticals [5]